{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:53:35Z","timestamp":1787003615534,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CMRPD1M0211"],"award-info":[{"award-number":["CMRPD1M0211"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In this research, we assessed mortality after major bleeding events in atrial fibrillation (AF) patients taking four direct oral anticoagulants (DOACs). Drawing data from the Taiwan National Health Insurance Research Database between 2016 and 2019, we focused on AF patients on DOACs who had major bleeding episodes. Using propensity score stabilized weighting, we established four comparable pseudo-DOAC groups. Among 2770 patients (460 dabigatran, 1322 rivaroxaban, 548 apixaban, 440 edoxaban), 85.3% were prescribed low-dose regimens. The 7-day mortality rate was 9.0%, surging to 16.0% by the 30th day. Compared with dabigatran, there was a distinct divergence in 7-day mortality of factor Xa inhibitors (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.012), with hazard ratios of 1.83 (95% CI 1.11\u20133.00,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.017) for rivaroxaban, 2.13 (95% CI 1.23\u20133.66,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.007) for apixaban, and 2.41 (95% CI 1.39\u20134.19,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.002) for edoxaban. This pattern remained consistent when analyzing the subgroup that received lower dosages of DOACs. In conclusion, factor Xa inhibitors were associated with a significantly higher risk of 7-day mortality following major bleeding events than dabigatran among AF patients.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-55500-z","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T10:02:40Z","timestamp":1709028160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Mortality after major bleeding in Asian atrial fibrillation patients receiving different direct oral anticoagulants: a nationwide, propensity score study"],"prefix":"10.1038","volume":"14","author":[{"given":"Jiun-Hao","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Ru","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Kuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai-Chu","family":"See","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,27]]},"reference":[{"key":"55500_CR1","doi-asserted-by":"publisher","first-page":"e003725","DOI":"10.1161\/JAHA.116.003725","volume":"5","author":"X Yao","year":"2016","unstructured":"Yao, X. et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J. Am. Heart Assoc. 5, e003725 (2016).","journal-title":"J. Am. Heart Assoc."},{"key":"55500_CR2","doi-asserted-by":"publisher","first-page":"e008150","DOI":"10.1161\/JAHA.117.008150","volume":"7","author":"YH Chan","year":"2018","unstructured":"Chan, Y. H. et al. Efficacy and safety of apixaban, dabigatran, rivaroxaban, and warfarin in Asians with nonvalvular atrial fibrillation. J. Am. Heart Assoc. 7, e008150 (2018).","journal-title":"J. Am. Heart Assoc."},{"key":"55500_CR3","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff, C. T. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet 383, 955\u2013962 (2014).","journal-title":"Lancet"},{"key":"55500_CR4","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.annemergmed.2019.09.001","volume":"76","author":"CW Baugh","year":"2020","unstructured":"Baugh, C. W. et al. Anticoagulant reversal strategies in the emergency department setting: Recommendations of a multidisciplinary expert panel. Ann. Emerg. Med. 76, 470\u2013485 (2020).","journal-title":"Ann. Emerg. Med."},{"key":"55500_CR5","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1161\/STROKEAHA.119.025623","volume":"50","author":"W-H Cheng","year":"2019","unstructured":"Cheng, W.-H. et al. Low-dose rivaroxaban and risks of adverse events in patients with atrial fibrillation. Stroke 50, 2574\u20132577 (2019).","journal-title":"Stroke"},{"key":"55500_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1253\/circj.CJ-18-0991","volume":"83","author":"N Murata","year":"2019","unstructured":"Murata, N. et al. Clinical outcomes of off-label dosing of direct oral anticoagulant therapy among Japanese patients with atrial fibrillation identified from the SAKURA AF Registry. Circ. J. 83, 727\u2013735 (2019).","journal-title":"Circ. J."},{"key":"55500_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014177","volume":"9","author":"HT Yu","year":"2020","unstructured":"Yu, H. T. et al. Label adherence of direct oral anticoagulants dosing and clinical outcomes in patients with atrial fibrillation. J. Am. Heart Assoc. 9, e014177 (2020).","journal-title":"J. Am. Heart Assoc."},{"key":"55500_CR8","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/bloodadvances.2020003560","volume":"5","author":"J-P Bassand","year":"2021","unstructured":"Bassand, J.-P. et al. Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: Results from the GARFIELD-AF registry. Blood Adv. 5, 1081\u20131091 (2021).","journal-title":"Blood Adv."},{"key":"55500_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.chest.2019.04.108","volume":"156","author":"Y-H Chan","year":"2019","unstructured":"Chan, Y.-H. et al. Effectiveness and safety of four direct oral anticoagulants in Asian patients with nonvalvular atrial fibrillation. Chest 156, 529\u2013543 (2019).","journal-title":"Chest"},{"key":"55500_CR10","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1111\/jth.14131","volume":"16","author":"Z Wolfe","year":"2018","unstructured":"Wolfe, Z., Khan, S., Nasir, F., Subramanian, C. R. & Lash, B. A systematic review and Bayesian network meta-analysis of risk of intracranial hemorrhage with direct oral anticoagulants. J. Thromb. Haemost. 16, 1296\u20131306 (2018).","journal-title":"J. Thromb. Haemost."},{"key":"55500_CR11","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.jacc.2012.03.019","volume":"60","author":"GY Lip","year":"2012","unstructured":"Lip, G. Y., Larsen, T. B., Skj\u00f8th, F. & Rasmussen, L. H. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J. Am. Coll. Cardiol. 60, 738\u2013746 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"key":"55500_CR12","doi-asserted-by":"crossref","unstructured":"Hsieh, C.-Y. et al. Taiwan\u2019s national health insurance research database: past and future. Clinical epidemiology, 349\u2013358 (2019).","DOI":"10.2147\/CLEP.S196293"},{"key":"55500_CR13","doi-asserted-by":"publisher","first-page":"e0122480","DOI":"10.1371\/journal.pone.0122480","volume":"10","author":"M Brabrand","year":"2015","unstructured":"Brabrand, M., Lassen, A. T., Knudsen, T. & Hallas, J. Seven-day mortality can be predicted in medical patients by blood pressure, age, respiratory rate, loss of independence, and peripheral oxygen saturation (the PARIS score): A prospective cohort study with external validation. PLoS One 10, e0122480 (2015).","journal-title":"PLoS One"},{"key":"55500_CR14","doi-asserted-by":"publisher","first-page":"e040837","DOI":"10.1136\/bmjopen-2020-040837","volume":"11","author":"M-J Hsieh","year":"2021","unstructured":"Hsieh, M.-J. et al. Developing and validating a model for predicting 7-day mortality of patients admitted from the emergency department: An initial alarm score by a prospective prediction model study. BMJ Open 11, e040837 (2021).","journal-title":"BMJ Open"},{"key":"55500_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejim.2016.08.010","volume":"36","author":"R Conway","year":"2016","unstructured":"Conway, R., Cournane, S., Byrne, D., O\u2019Riordan, D. & Silke, B. Time patterns in mortality after an emergency medical admission; relationship to weekday or weekend admission. Eur. J. Intern. Med. 36, 44\u201349 (2016).","journal-title":"Eur. J. Intern. Med."},{"key":"55500_CR16","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1161\/CIRCULATIONAHA.113.002332","volume":"128","author":"A Majeed","year":"2013","unstructured":"Majeed, A. et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 128, 2325\u20132332 (2013).","journal-title":"Circulation"},{"key":"55500_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.chest.2017.02.009","volume":"152","author":"Y Xu","year":"2017","unstructured":"Xu, Y. et al. Direct oral anticoagulant-or warfarin-related major bleeding: characteristics, reversal strategies, and outcomes from a multicenter observational study. Chest 152, 81\u201391 (2017).","journal-title":"Chest"},{"key":"55500_CR18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/ageing\/afq059","volume":"39","author":"B Pamukcu","year":"2010","unstructured":"Pamukcu, B., Lip, G. Y. & Lane, D. A. Simplifying stroke risk stratification in atrial fibrillation patients: Implications of the CHA2DS2\u2013VASc risk stratification scores. Age Ageing 39, 533\u2013535 (2010).","journal-title":"Age Ageing"},{"key":"55500_CR19","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1182\/bloodadvances.2017010694","volume":"2","author":"S Shah","year":"2018","unstructured":"Shah, S. et al. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Adv. 2, 200\u2013209 (2018).","journal-title":"Blood Adv."},{"key":"55500_CR20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","volume":"13","author":"S Xu","year":"2010","unstructured":"Xu, S. et al. Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health 13, 273\u2013277 (2010).","journal-title":"Value Health"},{"key":"55500_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1037\/1082-989X.9.4.403","volume":"9","author":"DF McCaffrey","year":"2004","unstructured":"McCaffrey, D. F., Ridgeway, G. & Morral, A. R. Propensity score estimation with boosted regression for evaluating causal effects in observational studies. Psychol. Methods 9, 403 (2004).","journal-title":"Psychol. Methods"},{"key":"55500_CR22","doi-asserted-by":"publisher","first-page":"e18174","DOI":"10.1371\/journal.pone.0018174","volume":"6","author":"BK Lee","year":"2011","unstructured":"Lee, B. K., Lessler, J. & Stuart, E. A. Weight trimming and propensity score weighting. PloS One 6, e18174 (2011).","journal-title":"PloS One"},{"key":"55500_CR23","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin, P. C. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat. Med. 28, 3083\u20133107 (2009).","journal-title":"Stat. Med."},{"key":"55500_CR24","first-page":"250","volume":"188","author":"F Li","year":"2019","unstructured":"Li, F., Thomas, L. E. & Li, F. Addressing extreme propensity scores via the overlap weights. Am. J. Epidemiol. 188, 250\u2013257 (2019).","journal-title":"Am. J. Epidemiol."},{"key":"55500_CR25","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1016\/j.jacc.2017.09.1087","volume":"70","author":"X Yao","year":"2017","unstructured":"Yao, X. et al. Renal outcomes in anticoagulated patients with atrial fibrillation. J. Am. Coll. Cardiol. 70, 2621\u20132632 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"55500_CR26","doi-asserted-by":"publisher","first-page":"e0269096","DOI":"10.1371\/journal.pone.0269096","volume":"18","author":"I-K Wang","year":"2023","unstructured":"Wang, I.-K. et al. Renal function is associated with one-month and one-year mortality in patients with intracerebral hemorrhage. Plos One 18, e0269096 (2023).","journal-title":"Plos One"},{"key":"55500_CR27","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1046\/j.1523-1755.2001.0590041510.x","volume":"59","author":"E Fiaccadori","year":"2001","unstructured":"Fiaccadori, E. et al. Incidence, risk factors, and prognosis of gastrointestinal hemorrhage complicating acute renal failure. Kidney Int. 59, 1510\u20131519 (2001).","journal-title":"Kidney Int."},{"key":"55500_CR28","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","volume":"76","author":"M Hori","year":"2012","unstructured":"Hori, M. et al. Rivaroxaban vs warfarin in Japanese patients with atrial fibrillation\u2013the J-ROCKET AF study. Circul. J. 76, 2104\u20132111 (2012).","journal-title":"Circul. J."},{"key":"55500_CR29","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1253\/circj.CJ-13-0726","volume":"77","author":"M Delgado-Fern\u00e1ndez","year":"2013","unstructured":"Delgado-Fern\u00e1ndez, M. The J-ROCKET AF study: A matter of ethnicity or a matter of weight?. Circul. J. 77, 2636 (2013).","journal-title":"Circul. J."},{"key":"55500_CR30","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.jacc.2016.06.062","volume":"68","author":"Y-H Chan","year":"2016","unstructured":"Chan, Y.-H. et al. Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in Asians with nonvalvular atrial fibrillation. J. Am. Coll. Cardiol. 68, 1389\u20131401 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"55500_CR31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1161\/STROKEAHA.118.023093","volume":"50","author":"MS Cho","year":"2019","unstructured":"Cho, M. S. et al. Outcomes after use of standard-and low-dose non\u2013vitamin K oral anticoagulants in Asian patients with atrial fibrillation. Stroke 50, 110\u2013118 (2019).","journal-title":"Stroke"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55500-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55500-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55500-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T10:11:14Z","timestamp":1709028674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55500-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,27]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["55500"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-55500-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,27]]},"assertion":[{"value":"30 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4771"}}